Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NOTE’s Year-end Report 2018

Financial performance October–December• Sales increased by 22% to SEK 396.5 (325.0) million.• Operating profit rose by 24% to SEK 28.1 (22.6) million.• Operating margin expanded by 0.1 percentage points to 7.1% (7.0%).• Profit after financial items increased by 25% to SEK 27.1 (21.6) million.• Profit after tax rose to SEK 24.0 (17.8) million, corresponding to SEK 0.83 (0.62) per share.• Cash flow after investments, including acquisition, amounted to SEK -80.8 (1.8) million, or SEK -2.80 (0.06) per share. Financial performance January–December• Sales increased by 17% to SEK

Evolution Crowned Online Casino Supplier of the Year at Global Gaming Awards London

Evolution Gaming, leading provider of Live Casino solutions, has been named Online Casino Supplier of the Year at Global Gaming Awards London 2019.Evolution beat nine other shortlisted companies to win the prestigious international award, which recognises the strongest, most innovative online casino suppliers over the last 12 months. Evolution received its award at the Global Gaming 2019 Awards Ceremony at The Hippodrome Casino in London ahead of ICE London. After collecting the award, Evolution’s Group CEO Martin Carlesund said: “We are thrilled to have won this award. The past twelve

Reminder: Invitation to presentation of Orkla's fourth quarter 2018 results, Wednesday 6 February

Orkla will report its fourth quarter 2018 results on Wednesday, 6 February at 7.00 a.m. CET. The quarterly report and the presentation material will be available at this time at www.orkla.com. The quarterly results will be presented at 8.00 a.m. in Oslo Concert Hall, Munkedamsveien 14, Oslo. The presentation and subsequent Q&A session will be held in English and may be viewed in a live webcast at www.orkla.com or followed by telephone. Dial-in details: +47 21 03 33 94. Pincode: 1661193. Orkla ASA Oslo, 5 February 2019 Ref.: IR & Communications Manager Elise Heidenreich

Lease agreement signed for plant site in Denmark – one step closer to establishment for Enviro and Windspace A/S

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. Elysium Nordic ApS, a prospective joint venture of Enviro and WindSpace A/S, has signed a lease agreement with Associated Danish Ports (ADP) effective February 5, 2019 for a site in Nyborg harbor on Funen, Denmark. The land lease is valid for 20 years with an option for additional 15 years. The agreement also includes a 5 years’ option to extend the leased area to enable a phase two of the project that will

Elisa’s transfer of company’s own shares

ELISA STOCK EXHANGE RELEASE 5 FEBRUARY 2019 AT 9:15 AMBasis for disposal: Based on the Board of Directors' decision, Elisa will transfer the shares to persons belonging to the Performance Share Plan 2014 for the performance period 2016–2018. The shares will be transferred today 5 February 2019. Trading code: ELISANumber of shares: 174,544Price/share: gratuitous After the transfer, Elisa holds a total of 7,437,277 treasury shares. ELISA CORPORATION Mr. Vesa SahivirtaIR Directortel. +358 50 520 5555 Distribution: Nasdaq HelsinkiPrincipal mediawww.elisa.com

US FDA grants Breakthrough Therapy Designation

5 February 2019 07:05 GMT US FDA grants Breakthrough Therapy Designationfor potential next-generation RSV medicine MEDI8897 Designation based on positive primary analysis of the Phase IIbtrial that demonstrated the safety and efficacy of MEDI8897 AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower

Gaming Innovation Group: Invitation to Q4 2018 results presentation

Gaming Innovation Group Inc. (GiG) publishes its interim report for the fourth quarter (October – December) 2018 before market opening on Monday 11 February 2019. CEO Robin Reed will present the Q4 results at 10:00 CET at Helio GT 30, Grev Turegatan 30, Stockholm. The presentation will be given in English and available live via webcast and via a telephone link. Questions can be asked via the weblink. Link to the webcast: https://tv.streamfabriken.com/gig-q4-2018  Dial-in numbers for participation in the telephone conference: Norway: +4723500236 Sweden: +46856642703

European Entertainment Intressenter BidCo AB holds approximately 97.1 percent of the shares in Cherry AB (publ) after the expiry of the extended acceptance period

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States of America, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. PRESS RELEASE

Year-end Report 2018

ESTABLISHMENT OF THREE INDEPENDENT AND LISTABLE COMPANIESFOURTH QUARTER[1] · Net sales increased to SEK 1,037.7 (1,199.9) million -    Qliro Financial Services increased the loan book by 45% and total operating income by 26%  -    Nelly increased its number of customers by 11%, order intake by 6% and net sales by 1% -    CDON Marketplace’s transformation led to an increase in external merchants´ sales by 20% while net sales decreased by 24% · The gross margin increased by 1.2 percentage points to 23.0 (21.8) percent   · Operating income before depreciation, amortization and

Strong sales growth

Fourth quarter · Net sales increased by 15% to SEK 23,167 M (20,109), with organic growth of 6% (5) and acquired net growth of 3% (3) · Very strong sales growth in Americas and Asia Pacific. Strong growth for Global Technologies, good growth in EMEA and growth in Entrance Systems · Five acquisitions have been signed with combined expected annual sales of about SEK 800 M · A new manufacturing footprint program was launched at year-end. The total estimated cost amounts to around SEK 1,500 M with a pay-back time of less than three years · Operating income 2) (EBIT)amounted to

Operations update

EnQuest PLC, 5 February 2019  Operations update  Good 2018 production performance, cost control and cash generation;  Expect c.20% production growth to between 63,000 Boepd and 70,000 Boepd in 2019 with a continued focus on debt reduction     2018 performance  ·  Average Group production up 48% at 55,447 Boepd compared to 2017; above the mid-point of revised guidance  ·  Strong performance at Magnus, with 100% interest delivering 21,528 Boepd in December, above expectations; high uptime, additional gas export and successful well interventions  ·  Kraken average

YEAR END REPORT 2018

Kai Wärn, President and CEO: “The result for the seasonally small fourth quarter was in line with our expectations, impacted by the effects from the challenging conditions earlier in the year. Net sales for the Group, adjusted for changes in exchange rates, were flat at SEK 6,470m. Higher costs for raw materials, tariffs and logistics, as well as continued investments in our strategic growth initiatives had a negative impact on our results. In total, the Group's operating profit, excluding restructuring related expenses, amounted to SEK -282m (-70) in the fourth quarter. We took

EMA grants PRIME eligibility for MEDI8897

5 February 2019 07:00 GMT EMA grants PRIME eligibility for potentialnext-generation RSV medicine MEDI8897 First EMA PRIME eligibility for AstraZeneca Eligibility based on positive primary analysis of thePhase IIb trial to evaluate the safety and efficacy of MEDI8897 AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency (EMA) has granted access to its PRIME (PRIority MEdicines) scheme for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for

Primex Pharmaceuticals appoints Alan Knox as Group CEO

Zug and Helsinki, 5th February 2019, Swiss Pharmaceutical company Primex Pharmaceuticals AG confirms the appointment of Alan Knox as Group CEO taking over from Kari Sarvanto who has decided to step down.Alan Knox is an international Pharmaceutical executive with over 30 years in the industry, launching brands globally, also within the anaesthesia sector. He has held Managing director positions with AstraZeneca in the Philippines and with Sandoz in Poland. Prior to joining Primex, Alan was VP Global portfolio strategy for MSD leading their Diversified brands based in both USA and Switzerland.

Saab Signs Support Contract for Giraffe AMB with France

Saab has signed a contract with the French Ministry of Defence’s Direction de la Maintenance Aéronautique (DMAé) regarding support for the surface based radar system Giraffe AMB.DMAé is responsible for the operational maintenance of the French Ministry of Defence’s aeronautics equipment. The contract, which includes support, maintenance and spare parts, covers an initial two-year period from January 2019 to January 2021, with options to extend for up to five additional years, to 2026. “Long-term support is a key part of Saab’s offer and we look forward to continuing our long-standing

The convertible bond issue in Ripasso Energy AB is covered by subscription undertakings corresponding to approximately 77 percent

On 16 January 2019, an Extraordinary General Meeting in Ripasso Energy AB resolved to carry out an issue of convertible bonds of not more than SEK 79,505,021 with preferential right for existing shareholders. The issue is covered by subscription undertakings equivalent to approximately 77 percent. The record date is 7 February 2019 and the last day of trading in shares in Ripasso Energy including rights to receive subscription rights is today on 5 February 2019.The purpose of the convertible loan is to meet Ripasso Energy's working capital needs related to the order by Afarak Mogale (Pty)

The first dexterous and sentient hand prosthesis has been successfully implanted

A female Swedish patient with hand amputation has become the first recipient of an osseo-neuromuscular implant to control a dexterous hand prosthesis. In a pioneering surgery, titanium implants were placed in the two forearm bones (radius and ulnar), from which electrodes to nerves and muscle were extended to extract signals to control a robotic hand and to provide tactile sensations. This makes it the first clinically viable, dexterous and sentient prosthetic hand usable in real life. The breakthrough is part of the European project DeTOP. The new implant technology was developed in

Arla to bring 40 million wood-based packages into supermarkets

(UPM, Helsinki, 05 February 2019 at 09:00 EET) - Arla wants to provide consumers with new opportunities to choose more responsible products. This year, Arla has been the first company in Finland to use renewable wood-based bioplastics in gable top paperboard cartons for milk, yoghurt and cooking products.The tall oil-based raw material is a Finnish innovation by UPM. As a result of the revamp, more than 40 million Arla packages will become more environmentally-friendly in 2019 to reflect consumers' wishes. Bioplastic is well suited to dairy product packaging as it has the same

Ossur Hf : Annual Report 2018

Announcement no. 8/2019Annual Report 20185 February 2019 Össur's Annual Report 2018 has just been published and is available for download at the link below. Online version of the Annual Report 2018 is available at https://annual-report.ossur.com/ Further information David Hreidarsson, Investor Relations, dhreidarsson@ossur.com, +354 515 1380 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors About Össur Össur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopaedics that

Ossur Hf : Interim report Q4 2018

Announcement no. 7/2019Interim report Q4 20185 February 2019 Highlights · Sales growth of 12% in local currency in Q4 2018, organic sales growth of 4% and reported growth of 9%. Sales growth of 7% in local currency in FY 2018, organic growth of 5% and 8% reported growth. · The prosthetics segment grew 6% organic in Q4 2018 and the B&S segment grew 3% organic. Growth in both business segments can be attributed to strong sales of high-end innovative products. · Gross profit margin was 64% in Q4 2018 compared to 63% in the comparable quarter. The increase is driven by

Bactiguard focuses operations in MEA

Bactiguard focuses operations in the Middle East and transfers its distribution to Iraq to a European distributor that, at the same time, takes over accounts receivable at a book value of SEK 17.1 million. The proceeds amount to SEK 12.8 million and, therefore, a write-down of accounts receivable corresponding to the balance of SEK 4.3 million is made in the accounts for 2018. The positive cash flow will be generated when the proceeds are paid in the first quarter of 2019.Bactiguard has been active in the Middle East for a number of years. In most markets, we have established strong

Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018

Financial report for the period 1 January to 31 December 2018 Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018 HIGHLIGHTS · Revenue reached DKK 18,117 million in 2018 representing an increase of 5% (8% in local currencies) compared to 2017 · Revenue of Abilify Maintena® increased 20% to DKK 1,595 million (23% in local currencies) · Revenue of Brintellix®/Trintellix® increased 31% to DKK 2,182 million (37% in local currencies) · Revenue of Northera® increased 10% to DKK 1,806 million (15% in local currency) · Revenue of

Resurs Holding Year-end Report January—December 2018

“We ended 2018 with continued profitable growth and a strong trend in underlying earnings. All in all for 2018, we can present our best ever full-year earnings and we delivered on or over all financial targets.” Kenneth Nilsson, CEO Resurs Holding AB1 October—31 December 2018* · Lending to the public rose 16% to SEK 27,957 million · Operating income increased 9% to SEK 883 million · Operating profit increased 1% to SEK 375 million · Earnings per share fell 2% to SEK 1.42 · C/I before credit losses (excl. Insurance) was 40.7% (39.4%) · The credit loss ratio was 2.0% (1.9%)

There are no items matching the current filter
There are no more items matching the current filter
Back to top